National Cancer Prevention Month 2026: Build prevention into routine operations, not a once-a-year message

Branded National Cancer Prevention Month 2026 hero featuring an executive operating route from risk assessment through prevention support, screening, service completion, and follow-up.
Greg Wahlstrom, MBA, HCM
Branded National Cancer Prevention Month 2026 hero featuring an executive operating route from risk assessment through prevention support, screening, service completion, and follow-up.
February 1 to 28, 2026 · Executive Brief

National Cancer Prevention Month 2026

Build prevention into routine operations, not a once-a-year message.

The 2026 leadership signal

Cancer prevention is a portfolio of reliable systems.

Cancer is not one disease, and prevention is not one behavior. The evidence spans tobacco treatment, vaccination against cancer-causing infections, ultraviolet protection, occupational and environmental protections, healthy living supports, risk-informed counseling, and recommended screening for selected cancers.

Prevention and screening also require careful language. Screening looks for cancer or precancerous changes in people without symptoms and can have benefits and harms. It does not replace evaluation of a symptom. Risk reduction lowers probability at a population or individual level, but it does not make anyone responsible for developing cancer.

The executive opportunity is to govern this portfolio as an access and completion system. Eligibility logic, outreach, shared decision-making, appointments, coverage, results, diagnostic follow-up, and longitudinal support must connect. A campaign impression is not the outcome. A completed, equitable care pathway is.

Executive priority

Select one prevention service and one screening pathway, then measure both from eligibility through completed action and documented follow-up.

Potentially preventable burdenAbout 40%

AACR reports that about 40% of U.S. cancer cases can be attributed to preventable causes such as smoking, excess body weight, physical inactivity, and excessive sun exposure. This is a population estimate, not an explanation for any individual's cancer.

Progress through prevention and screening5.94 million

AACR reports an estimated 5.94 million cancer deaths averted from 1975 through 2020 through public health interventions regarding cancer prevention and screening.

Figures are summarized from the authoritative sources linked below. Definitions and denominators should be read with each source.

System route

Separate risk reduction, screening, and symptom evaluation.

A safe route makes each purpose clear and gives every next step an accountable owner.

  1. Assess risk and eligibility

    Use current authoritative guidance, personal and family history, age, prior results, exposures, and clinical judgment. Avoid treating a population rule as an individualized recommendation without review.

  2. Offer prevention support

    Make evidence-based tobacco treatment, indicated vaccination, sun protection, healthy living support, and occupational or environmental safeguards accessible without blame or moral judgment.

  3. Support an informed screening decision

    Explain the purpose, possible benefits, limitations, and harms in understandable language. Record the decision and the next opportunity for review when screening is deferred.

  4. Complete the service

    Resolve scheduling, preparation, language, transportation, coverage, and paid-time barriers. Track completion rather than relying on orders or reminders.

  5. Close every result

    Assign review, communication, and diagnostic follow-up for abnormal or indeterminate results. Keep symptom evaluation on a separate urgent route when clinically indicated.

Reliability rule: The most responsible prevention message acknowledges structural barriers, inherited risk, uncertainty, and the fact that people who follow every recommendation can still develop cancer.

Operating dashboard

Follow the prevention pathway from eligibility to resolution.

Use denominators that reflect true eligibility and display where access or completion differs across populations.

01

Eligible reach

Measure whether eligible people receive an offer, recommendation, or shared decision conversation using the current approved criteria.

MeasureEligible population reached
02

Completed prevention

Track completion of the selected vaccination, tobacco treatment, or other prevention service rather than education alone.

MeasurePrevention service completion rate
03

Screening completion

Measure completed screening among eligible people and document informed decisions when the service is declined or deferred.

MeasureEligible screening completed or decision documented
04

Abnormal result closure

Follow abnormal and indeterminate results until the required diagnostic step is completed or an accountable clinician documents resolution.

MeasureResults closed within the approved interval
05

Equity view

Stratify reach, completion, and closure by locally appropriate demographic and access factors.

MeasureLargest material gap at each pathway stage
Warm handoff

Do not let the result become the patient's navigation problem.

The handoff should preserve the purpose of the service, the result, the level of concern, and the next accountable action.

Prevention lane

Risk review to prevention service

  1. Confirm eligibility or clinical rationale under current guidance.
  2. Connect the person to the service with cost and access support.
  3. Document completion, contraindication, informed deferral, or the next review date.
Screening lane

Decision to completed screening

  1. Explain the option and confirm the person's informed choice.
  2. Schedule, prepare, and support completion in the appropriate setting.
  3. Assign result review and communication before the test occurs.
Diagnostic lane

Abnormal result to resolution

  1. Communicate what the result means and does not mean in plain language.
  2. Schedule the appropriate diagnostic follow-up and identify the accountable clinician.
  3. Track completion and escalate missed or delayed steps under the approved standard.

A positive screening result is not itself a cancer diagnosis. Communications should distinguish screening, diagnostic evaluation, and confirmed diagnosis.

Executive scorecard

Five questions that expose prevention system gaps.

Use the scorecard to connect clinical guidance, access, result management, and equity in one review.

Use stable definitions and stratify results by site, population, and service line when appropriate.
Signal Executive question Accountable owner Review cadence
Eligibility Are rules current, clinically governed, and applied without excluding eligible populations? Clinical governance Quarterly and on guidance change
Access Where do cost, transportation, language, preparation, or scheduling barriers block completion? Patient access Monthly
Completion Are we measuring completed prevention and screening or only orders and outreach? Population health Monthly
Results Does every abnormal or indeterminate result have an owner, deadline, and escalation route? Quality and safety Monthly exception review
Equity Which pathway stage produces the largest completion gap, and what design change will address it? Health equity Quarterly
90-day plan

Make one prevention pathway demonstrably reliable.

Choose a defined population and avoid launching multiple campaigns before the result-closure system works.

Days 1 to 30

Choose and baseline

  • Select one prevention service and one screening pathway with meaningful local gaps.
  • Validate eligibility, exclusions, shared decision points, and escalation standards.
  • Baseline reach, completion, abnormal-result closure, and equity measures.
Days 31 to 60

Remove friction

  • Interview patients and front-line teams about the steps that most often fail.
  • Pilot scheduling, navigation, language, transportation, or cost interventions targeted to those failures.
  • Create one accountable queue for abnormal and indeterminate results.
Days 61 to 90

Govern and scale

  • Review every overdue diagnostic follow-up and resolve immediate safety risks.
  • Publish the pathway dashboard with named owners and an equity view.
  • Scale the successful design only after completion and closure improve.

Prevention is not a message. It is a completed route.

Healthcare leaders can reduce friction around evidence-based prevention and screening while communicating risk with accuracy and humility. The standard is not perfect compliance. It is an informed, equitable process that owns every next step.

Leadership actionSelect one overdue prevention or screening cohort and trace the pathway through completion and result closure. Remove the most common barrier within 90 days.

Authoritative resources

Safety note: Cancer risk is shaped by modifiable and nonmodifiable factors, and no prevention step eliminates risk. Screening recommendations vary by age, history, anatomy, prior results, exposures, and current guidance. People should make individual prevention and screening decisions with a qualified clinician. New or persistent symptoms require clinical evaluation even when screening is up to date.

AACR confirms the February observance and provides the cited population estimates. No formal 2026 campaign theme was published on its observance page.

Leave us a Comment